Herbalife, the US-listed nutrition company that sells through independent distributors, said on March 26, 2026 that it had agreed to acquire certain assets of Bioniq, a London-based company that makes personalised supplements from customer questionnaires and blood-test data.
Herbalife set the purchase price at $55 million, to be paid over five years, with an initial $10 million due when the deal closes. The transaction value also includes up to $95 million in contingent payments tied to future performance, which would bring the total to as much as $150 million. The companies did not say what targets trigger those payments.
The deal was expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. Bioniq founder and president Vadim Fedotov said he was joining Herbalife. Herbalife said Bioniq's products would be offered later in 2026 through its independent distributors to customers in selected European countries and the United States, with more markets to follow.
What Bioniq built
Fedotov launched Bioniq in London in 2019. The company builds a supplement formula for each customer based on a questionnaire about their health background and the results of blood tests, and adjusts ingredients and dosages to the nutrient deficiencies it finds. Herbalife's announcement said Bioniq uses a patented personalisation engine and a proprietary database of biomarkers, and that it has created formulas for hundreds of thousands of users while shipping worldwide.
Its customers range from everyday wellness buyers to professional athletes. When Bioniq raised its Series B in 2024, Tech.eu reported that the company sold in 60 countries, that the United States accounted for more than half of its customer base, and that its partners included the Lanserhof medical spa group and the UFC. The athletes Diogo Dalot and Andrei Kirilenko were named as users.
“The future of health and wellness is becoming more personalized and informed by data.”
An asset deal with a separate option
Herbalife is not buying all of Bioniq. The agreement covers certain assets of the personalised supplements business. Alongside it, Herbalife received a call option to acquire Bioniq LAB, which it described as a separate platform working on small molecules and peptides. Herbalife said the option gives it room to look at longer-term opportunities in that area without committing capital now.
The payment schedule also keeps most of the upfront cost low. Of the $55 million base price, $10 million is due at closing and the rest is spread across five years. The additional $95 million is only paid if the business performs, according to the release. Herbalife did not say whether payments would be made in cash or shares.
Why Herbalife is buying
Herbalife presented the purchase as a step towards becoming what it called a technology-enabled, data-driven health and wellness platform. Chief executive Stephan Gratziani said the company would combine Bioniq's supplement technology with Pro2col and its distributor network to sell personalised wellness products at a larger scale.
Pro2col and Link BioSciences are two earlier Herbalife acquisitions in personalised nutrition. Herbalife said Bioniq would let it offer a wider range of personalised supplements in several delivery formats, and that it planned to pair Bioniq's product with its own manufacturing operations. Herbalife has sold nutrition products through independent distributors since 1980 and says it is present in more than 90 markets.
Fedotov said in the announcement that he founded Bioniq to help people improve their wellbeing with nutrition informed by biomarker and lifestyle data, and that Herbalife's distributor network was a reason to join.
Ronaldo on both sides
Cristiano Ronaldo, the Portuguese footballer, has a stake in the deal from both directions. Herbalife described him as a long-time global nutrition partner of the company and as a Bioniq shareholder, and the announcement's subtitle presented the transaction as part of a joint commitment by Herbalife and Ronaldo to expand personalised nutrition. Ronaldo said in the release that he had used both Herbalife and Bioniq products and that personalised nutrition had been central to his performance.
Herbalife did not say how large Ronaldo's stake in Bioniq is or how much he stands to receive from the sale.
The funding behind Bioniq
Bioniq raised a $15 million Series B in July 2024, led by the European venture firms HV Capital and Unbound. The round valued the company at $75 million, Tech.eu and Silicon Canals reported at the time; Silicon Canals gave the round size as about €13.7 million. The company said then that it would spend the money on product development, including links with laboratory networks, and on expanding in the United States and the Middle East.
Herbalife's $55 million base price is below that 2024 valuation, although the deal covers only certain assets and the total could rise to $150 million if all contingent payments are made. Bioniq did not disclose its headcount or total funding.
